|
Accueil > Actualité
GSK: China to consider Nucala for COPD
(CercleFinance.com) - GSK announced on Thursday that the Chinese authorities had agreed to review its marketing application for Nucala in chronic obstructive pulmonary disease (COPD) with eosinophilic inflammation
The British pharmaceutical group explains that around 100 million Chinese suffer from COPD, which corresponds to almost 25% of the total affected population worldwide (390 million people). Nucala, a monoclonal antibody that blocks a protein called interleukin-5 (IL-5), is approved in some twenty countries for the treatment of asthma. In a completely different field, the Canadian government announced yesterday that it had purchased 500,000 doses of its human avian flu vaccine from GSK, with a view to protecting people at risk. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
21/02/2025 17:32
ADPpoursuit son repli, l'avis d'un analyste 21/02/2025 17:06 Rolls-Roycecontrat d'achat d'électricité avec SWU 21/02/2025 16:41 Airbusle satellite 'Biomass' de l'ESA en route pour Kourou 21/02/2025 16:30 KKRinvestit dans un complexe de logements à Stockholm 21/02/2025 15:45 Engiela Commission européenne approuve une aide d'Etat 21/02/2025 15:35 Repsolplombé par une dégradation de broker Tous les articles sociétés |
